The recognition of different molecular subtypes of breast cancer, namely luminal (divided into luminal A and B based on proliferation rate), HER2-amplified and triple-negative/basal-type, with different characteristics and clinical behavior2,3, has been critical for informing patient management. Here, ERBB2 is linked to breast carcinoma.